MicroRNAs Enter the Clinical Trials

Česká verzia

Authors: O. Slabý ^1,2
Authors place of work: Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno ¹; Středoevropský technologický institut, skupina Molekulární onkologie II – solidní nádory, Brno ²
Published in the journal: Klin Onkol 2012; 25(2): 139-142
Category: Oncology Highlights

Zdroje

1. Slaby O (ed). MicroRNAs in Solid Cancer: From Biomarkers to Therapeutic Targets. New York: Nova Science Publishers 2012.

2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75(5): 843–854.

3. Slaby O, Svoboda O, Michalek J et al. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009; 8: 102.

4. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4(3): 143–159.

5. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10): 775–789.

6. Bader AG, Brown D, Stoudemire J et al. Developing therapeutic microRNAs for cancer. Gene Ther 2011; 18(12): 1121–1126.

7. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327(5962): 198–201.

8. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467(7311): 86–90.

9. Moore LM, Zhang W. Targeting miR-21 in glioma: a small RNA with big potential. Expert Opin Ther Targets 2010; 14(11): 1247–1257.

10. Esquela-Kerscher A, Trang P, Wiggins JF et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008; 7(6): 759–764.

11. Yu F, Yao H, Zhu P et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131(6): 1109–1123.

12. Wiggins JF, Ruffino L, Kelnar K et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70(14): 5923–5930.

13. Liu C, Kelnar K, Liu B et al. The microRNA miR--34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17(2): 211–215.